The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for treatment of third-line or later (3L+) R/R follicular lymphoma (FL): Update with 24 months of liso-cel follow-up (FU).
 
Alexander Boardman
Honoraria - OncLive/MJH Life Sciences
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene
 
Juan Luis Reguera
Consulting or Advisory Role - BMS GmbH & Co. KG; Incyte; Janssen Oncology; Novartis
Speakers' Bureau - Amgen; Janssen; Kite/Gilead; Sanofi
Travel, Accommodations, Expenses - Janssen Oncology; Kite/Gilead
 
Pearl Wang
Consulting or Advisory Role - Employee of EVERSANA, which received funding from Bristol Myers Squibb to conduct this research.
 
Jenna Ellis
Consulting or Advisory Role - Employee of EVERSANA, which received funding from Bristol Myers Squibb to conduct this research.
 
Merav Bar
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Jinender Kumar
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Thalia Farazi
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Alejandro Martin Garcia-Sancho
Honoraria - Abbvie; BeiGene; BMS; Gilead Sciences; Ideogen; Janssen-Cilag; Roche; SOBI; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; BMS; Genmab; Gilead Sciences; GlaxoSmithKline; Ideogen; Incyte; Janssen; Kyowa Hakko Kirin; Lilly; Miltenyi Biomedicine; Novartis; Roche; SOBI
Expert Testimony - Gilead Sciences
Travel, Accommodations, Expenses - BMS; Gilead Sciences; Janssen Oncology; Roche
 
Koji Izutsu
Honoraria - AstraZeneca, Abbvie, Bristol Myers Squibb, Novartis, Pfizer, Janssen, Kyowa Kirin, Daiichi Sankyo, Chugai, Genmab, Gilead, Ono Pharmac, Nihon Kayakueutical, Symbio, Takeda, Lilly, Astellas, Meiji Seika Pharma
Consulting or Advisory Role - MSD, AstraZeneca, Abbvie, Bristol Myers Squibb, Novartis, Yakult, Kyowa Kirin, Chugai, Beigene, Genmab, Otsuka, Ono Pharma, Mitsubishi Tanabe Pharmaceutical, Eisai, Symbio, Taked, Zenyakua, Carna Biosciences, Nihon Shinyaku
Research Funding - MSD, AstraZeneca, Abbvie, Incyte, Bristol Myers Squibb, Novartis, Bayer, Pfizer, Janssen, Yakult, Kyowa Kirin, Daiichi Sankyo, Chugai, Beigene, Genmab, LOXO Oncology, Otsuka, Regeneron, Gilead (Inst)